Form 4 for MGNX MACROGENICS INC
Accepted 2024-04-08 00:00:00 ET · period of report 2024-04-04 · accession 0001125345-24-000079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-08 | 2024-04-04 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $4.82 | +42.5K | 51.4K | +478% | +$204.8K |
| DM | 2024-04-08 | 2024-04-04 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | S - Sale+OE | $15.55 | -51.4K | 0 | -100% | -$799.1K |
| D | 2024-04-08 | 2024-04-04 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $4.82 | -42.5K | 127.5K | -25% | -$204.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-04 | M | A | 42,500 | $4.82 | 51,395 | D | — | — | |
| 2 | Common | Common Stock | 2024-04-04 | S | D | 5,351 | $17.74 | 3,165 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $17.05 to $17.99. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2024-04-04 | S | D | 42,500 | $15.07 | 8,895 | D | — | — | |
| 4 | Common | Common Stock | 2024-04-04 | S | D | 147 | $15.51 | 8,748 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $15.07 to $15.94. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Common | Common Stock | 2024-04-04 | S | D | 232 | $16.38 | 8,516 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $16.01 to $16.58. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 6 | Common | Common Stock | 2024-04-04 | S | D | 3,165 | $18.22 | 0 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $18.00 to $18.84. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 7 | Derivative | Employee stock option (right to buy) | 2024-04-04 | M | D | 42,500 | $4.82 | 127,500 | D | $4.82 · — to 2033-02-15 | 42,500 Common Stock | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023. (F6) 12.5% of the shares underlying the grant become exercisable 6 months after the 2/15/2023 date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |